retatrutide trial safety clinical Retatrutide: Triple Agonist Weight Loss Drug Shows 24% Reduction – What to Know retatrutide mechanism retatrutide clinical trial

Patients with severe kidney disease (eGFR below 2030) Patients with recurrent UTIs or fungal infections Type 1 diabetes patients (unless specifically prescribed) Pregnant women References: Protective Influence of SGLT-2 Inhibitors Against Heart Failure PMC 2024 Clinical Evidence for Cardiovascular & Kidney Benefits PMC SGLT2 Inhibitors: Antidiabetic and Cardioprotective Effects PMC Emerging Horizons: SGLT-2 Inhibitors Beyond Diabetes PMC DPP-4 inhibitors, sulfonylureas, TZDs So far we have covered the star players Metformin, GLP-1 agonists, and SGLT2 inhibitors

Animal studies suggest BPC-157 may protect the gastrointestinal tract and accelerate healing in such cases

What Predicts Drug-Free Type 2 Diabetes Remission

doi: 10.1038/ismej.2011.191 27 Grigor'evaI

Thank you so much for listening to the Intermittent Fasting podcast